Earnings miss, higher guidance and new ALS data reshape the Corcept story

Corcept Therapeutics (CORT) has given investors a mixed update, pairing a first quarter net loss with higher 2026 revenue guidance and fresh two year survival data from its Phase 2 DAZALS ALS study.

The company reported a net loss of US$31.76 million for the quarter ended March 31, 2026, compared with net income of US$20.55 million a year earlier, with basic and diluted loss per share of US$0.30 from continuing operations.

At the same time, Corcept raised its 2026 revenue outlook to a range of US$950 million to US$1.05 billion, citing strong prescription trends and early FDA approval of Lifyorli for platinum resistant ovarian cancer as key contributors to its updated guidance.

On the pipeline side, management highlighted two year overall survival data from the DAZALS trial. Patients receiving 300 mg of dazucorilant daily experienced a reported reduction in risk of death compared with placebo groups that did not switch to the higher dose.

The stock closed at US$51.20 on the latest trading day. The share price was up over the past month and past three months but down over the past year, which may leave some investors weighing near term guidance against pipeline and legal risks.

Despite a recent 1 day share price decline of 2.07% to US$51.20 and legal headlines, Corcept’s 30 day share price return of 22.17% and 3 year total shareholder return of 112.80% suggest momentum has picked up again after a weaker 1 year total shareholder return of 29.03%.

If this kind of move has your attention, it could be a good moment to see what else is moving in healthcare and biotech via our curated list of 32 healthcare AI stocks

So with a higher 2026 revenue outlook, promising ALS data and a stock that is still trading below analyst price targets, is Corcept undervalued today, or has the market already priced in the company’s future growth?

Most Popular Narrative: 19.4% Undervalued

Corcept’s most followed narrative pegs fair value at $63.53 a share versus the recent $51.20 close, which points to a sizeable valuation gap according to Giuca.

Ottima azienda solida finanziariamente senza debiti a lungo e breve termine. Il FcF tende a diminuire nel tempo mentre aumentano i compensi per i vari membri del board che hanno uno skill in the game moderato. Calcolando il DCF , con un approccio un po ottimistico, quindi , valutando la crescita del fcf al 10% per i primi 5 annni e al 7% dal 6 al 10, calcolando un tasso di sconto al 12% e una crescita del 3% annuo (valore in linea con l aumento medio del pil Usa) il mio fair value è di circa 33 euro al quale sottraggo un MoS del 30% , quindi ho impostato l acquisto a 23 euro circa. Anche il P/E di 31 mi da un' indicazione del genere, Quindi attualmente è sopravvalutata.

The narrative leans heavily on robust profit margins, a firm discount rate and sustained free cash flow growth assumptions across the next decade, as well as a rich future earnings multiple. Curious which of those inputs does the real heavy lifting in getting from today’s price to that higher fair value.

Result: Fair Value of $63.53 (UNDERVALUED)

However, the story can shift quickly if DAZALS data underwhelms in later studies or if legal issues start to weigh on sentiment again.

Another angle on value: rich multiples versus the “undervalued” tag

There is a clear split between models here. While the narrative and fair value estimate point to Corcept trading below intrinsic value, the current P/E of 117.7x is far above the US Pharmaceuticals industry average of 16.1x, a peer average of 23.8x and a fair ratio of 36x. This combination signals meaningful valuation risk if sentiment cools.

For investors who prefer earnings based yardsticks over cash flow models, that wide gap in P/E is a reminder to stress test both upside and downside cases before acting.

Next Steps

With sentiment clearly split between rich multiples and an “undervalued” label, it makes sense to move quickly. Review the data yourself and decide where you stand based on your risk tolerance and time horizon, then weigh both sides through 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Corcept has sharpened your focus, do not stop here. Use targeted screeners to surface other stocks that better match your goals and risk comfort.

• Target dependable cash generators by reviewing companies in the solid balance sheet and fundamentals stocks screener (44 results).
• Spot potential value opportunities early by scanning the screener containing 21 high quality undiscovered gems.
• Prioritise resilience and support peace of mind by focusing on the 70 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.